SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-012650 to BGM Group Ltd. (BGM)

BGM Group Ltd.
Date: Nov. 15, 2024 · CIK: 0001779578 · Accession: 0000000000-24-012650

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-282998

Date
November 15, 2024
Author
Chen Xin
Form
UPLOAD
Company
BGM Group Ltd.

Letter

November 15, 2024 Chen Xin Chief Executive Officer BGM Group Ltd No. 152 Hongliang East 1st Street, No. 1703 Tianfu New District, Chengdu, 610200 People's Republic of China Re:BGM Group Ltd Registration Statement on Form F-3 Filed November 5, 2024 File No. 333-282998 Dear Chen Xin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Yu Wang, Esq.

Show Raw Text
November 15, 2024
Chen Xin
Chief Executive Officer
BGM Group Ltd
No. 152 Hongliang East 1st Street, No. 1703
Tianfu New District, Chengdu, 610200
People's Republic of China
Re:BGM Group Ltd
Registration Statement on Form F-3
Filed November 5, 2024
File No. 333-282998
Dear Chen Xin:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Yu Wang, Esq.